Randomized Study to Evaluate the Impact of Dietary Optimization on Metabolic Profile, Immunoactivation and Cardiovascular Risk in HIV Population on ART

What this Trial Is About

Researchers are investigating how adopting a Mediterranean diet may improve health outcomes in adults living with HIV who are on antiretroviral therapy (ART). People living with HIV often face chronic inflammation, metabolic issues, and higher cardiovascular risks partly due to the virus, immune activation, and ART side effects. This randomized clinical trial aims to evaluate whether dietary changes can reduce these risks and improve quality of life. The study will enroll 64 participants who will be randomly assigned to either a control group receiving standard dietary advice or an intervention group receiving personalized nutritional counseling to enhance adherence to the Mediterranean diet. The intervention includes tailored meal plans, education on food choices emphasizing fruits, vegetables, whole grains, healthy fats, and fish, and virtual follow-ups at weeks 4 and 12. The study duration is 48 weeks, with assessments at baseline, week 24, and week 48. Participants will undergo various evaluations including lipid profiles, inflammatory and immune activation markers, arterial stiffness measurements, and coronary plaque imaging via non-invasive techniques. They will also complete questionnaires on diet adherence, physical activity, and quality of life, alongside body measurements. The study monitors changes over time to assess the impact of dietary intervention on cardiovascular and metabolic health in people living with HIV.

Impact of Mediterranean Diet in Cardiovascular Risk Among People With HIV